REUTERS NEXT-Health care execs seek to better understand patient outrage after UnitedHealthcare killing

Reuters
2024-12-12

NEW YORK, Dec 11 (Reuters) - Health care companies are taking a step back to better understand patients' experiences after a powerful U.S. health insurance executive was murdered last week, executives from drugmaker Pfizer and Amazon.com said at a panel at the Reuters NEXT conference in New York on Wednesday.

"Our health system needs to be better ... There's a lot of things that should cause a lot of outrage," Amazon Pharmacy Chief Medical Officer Vin Gupta said. "It's also true that that should not have happened. There cannot be this false moral equivalence in our discourse."

Brian Thompson, the CEO of UnitedHealth's insurance arm, one of the largest health insurers in the U.S., was shot dead on the morning of Dec. 4 outside a hotel in Manhattan in what police said was a targeted attack.

Luigi Mangione, the suspect charged with the murder was arrested earlier this week in possession of a handwritten manifesto that offered insight into his mindset, according to police. The New York Times reported that an internal New York City Police report analyzing the document concluded that Mangione viewed the killing as a justified response to what he believed to be corruption in the healthcare industry.

"I think all of us are taking a step back and trying to understand what's happening with patients and their experiences," Pfizer Chief Sustainability Officer Caroline Roan said. "Clearly there's a larger dialogue that needs to happen, and we're going to be taking our time to try to understand exactly what happened and understand that feedback, and see where we can play a positive role."

To view the live broadcast of the World Stage go to the Reuters NEXT news page:

(Reporting by Michele Gershberg and Michael Erman Editing by Nick Zieminski)

((michael.erman@thomsonreuters.com;))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10